Open AccessImpact of Trastuzumab on Ipsilateral Breast Tumor Recurrence for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer after Breast-Conserving Surgery
Author(s) -
Jong-Ho Cheun,
Ji-Young Won,
Jessica Jung,
Hong-Kyu Kim,
Wonshik Han,
HanByoel Lee
Publication year - 2021
Publication title -
journal of breast cancer/journal of breast cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 36
eISSN - 2092-9900
pISSN - 1738-6756
DOI - 10.4048/jbc.2021.24.e33
Subject(s) - medicine , trastuzumab , human epidermal growth factor receptor 2 , breast cancer , oncology , epidermal growth factor receptor , cancer
Trastuzumab is effective in early and advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, few studies have reported the effect of trastuzumab on ipsilateral breast tumor recurrence (IBTR), whose incidence is higher in the HER2-positive subtype than in other subtypes.